Moreover, the translational relevance of targeting this axis in human patients remains unvalidated, as our in vivo experiments relied solely on xenograft models without clinical correlation to NAT10/FOXD1 co-expression patterns in NPC cohorts. This evidence concerns the gene FOXD1 and nasopharyngeal carcinoma.